Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune
 cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.

 PURPOSE: Phase I trial to study the effectiveness of bone marrow and peripheral stem cell
 transplantation in treating patients who have hematologic cancer.
OBJECTIVES:

 -  Determine the toxicity of unmanipulated bone marrow augmented with CD34+ enriched
 peripheral blood stem cells in patients with hematologic malignancies undergoing
 allogeneic transplantation.

 -  Evaluate this treatment regimen in terms of kinetics of hematopoietic engraftment,
 infection, severity of graft-vs-host disease, relapse rate, and cost effectiveness in
 this patient population.

 OUTLINE: Patients undergo allogeneic transplantation comprising unmanipulated bone marrow
 with filgrastim (G-CSF)-mobilized, CD34+ enriched peripheral blood stem cells on day 0.

 Patients receive graft-vs-host disease prophylaxis comprising cyclosporine IV over 24 hours
 on day -1 and methylprednisolone IV or oral prednisone daily on days 7-65. Patients also
 receive G-CSF subcutaneously daily until blood counts recover.

 Patients are followed weekly for 3 months, at 6 months and 1 year, and then annually for 5
 years.

 PROJECTED ACCRUAL: A total of 30-60 patients will be accrued for this study.
DISEASE CHARACTERISTICS:

 -  Diagnosed hematologic malignancy that is eligible for an active allogeneic bone marrow
 transplantation protocol and leukemia, lymphoma, myeloma, and aplastic anemia
 treatment protocols

 -  HLA-identical or one antigen-mismatched related donor

 PATIENT CHARACTERISTICS:

 Age:

 -  10 to 65

 Performance status:

 -  Not specified

 Life expectancy:

 -  Not specified

 Hematopoietic:

 -  Not specified

 Hepatic:

 -  Not specified

 Renal:

 -  Not specified

 Other:

 -  No known sensitivity to E. coli derivatives

 PRIOR CONCURRENT THERAPY:

 -  See Disease Characteristics